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To translate scientific discovery into improved health,
we must study health care itself; i.e., how people access
health care, costs or other barriers to the provision of
good care, and what happens to patients as a result of
this care. Health services research (HSR) is the inter-
disciplinary field that studies health care and its effects.
This paper reviews different types of HSR and high-
lights some dermatologic examples that have resulted
in improved health-care systems or have helped us
understand access to existing systems. The paper also
addresses some of the political and systematic chal-
lenges for health services research overall, and for
individual investigators and program leaders.
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INTRODUCTION
We think that ‘‘You get what you pay for’’, but the platitude
does not apply to health. For example, despite spending more
than any country in the world on basic research and medical
care, the US overall has relatively poor health by most
metrics (Davis et al., 2010). To figure out why, we need
health services research (HSR). To translate scientific
discovery into improved health, we must study health care;
i.e., how people access health care, costs or other barriers to
the provision of good care, and what happens to patients as a
result of this care (AHRQ, 2002).
In this paper, I will define HSR, and will describe some of
the reasons why it has not fully spearheaded the translation of
science into health. I will highlight some examples from
dermatology that have resulted in improved health-care
systems or have helped us understand access to existing
systems. I will also point out some of the challenges to the
field in the next decade, and will suggest some potential
solutions.
WHAT IS HEALTH SERVICES RESEARCH?
Health services research is an interdisciplinary field that
studies health care itself, and its effects. The methods of HSR
are those of the social sciences, including epidemiology,
biostatistics, economics, sociology, anthropology, and psy-
chology, but the focus of HSR studies is different; for HSR, the
goal is, most simply, to assess the provision and quality of
health care.
The continuum of clinical research is depicted in the
Figure 1. In so-called T1 translational research, basic
biomedical research at the bench, focused largely on
molecular medicine, is translated into potentially efficacious
therapies to treat disease at the bedside in patients.
The cornerstone of this efficacy research is the clinical trial
(which is discussed in another paper). In T2 translational
research, efficacious therapies may be demonstrated to be
effective in the population of patients with a condition.
Archie Cochrane, a premier clinical epidemiologist of
the past century, referred to the research questions in
efficacy research as ‘‘Can this work?’’ and in effectiveness
research as ‘‘Does this work?’’ (Haynes, 1999). The health
services researcher focuses farther along the continuum,
and asks ‘‘Is this working to improve health overall?’’
Subsets of HSR include, for example, outcomes research
(in which the effects of a condition or treatment on a patient
or society are precisely measured) and implementation
research (which studies the adoption of research findings
into routine health care). The overall goal, however, is to
learn how health care can best and most efficiently improve
health.
HSR studies themselves can be basic or applied (Vargas
et al., 2004). For example, the development of outcomes
measures or risk adjustment methods provides tools that can
then be used for measuring and comparing care in highly
rigorous ways. Similarly, health services researchers often
develop and use advanced statistical methods to analyze
complex clinical data about care and its provision. Applied
HSR, on the other hand, can seem almost activist in its
outlook, as it often addresses or informs pressing questions
that have significant policy implications. For example, why is
there disparity in melanoma stage at diagnosis among
patients of different races (Hu et al., 2009)? Why are there
unexplained variations in care for skin conditions seen in
different practice settings (Chren et al., 2004)? How often do
medical errors and adverse events occur in dermatologic
practice, and how can they be reduced (Gawkrodger, 2011)?
Addressing these types of questions requires the multi-
disciplinary resources of HSR.
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HEALTH SERVICES RESEARCH AND POLITICS
At first glance, it seems as if research that is highly practical,
and that provides the basis for determining the quality and
value of a nation’s investment in health research and health
care, should be politically and popularly noncontroversial. In
fact, the National Institute for Health and Clinical Excellence
was established in 1999 by the National Health Service in the
UK to provide evidence-based recommendations about
strategies to improve health (http://www.nice.org.uk/).
In the US, however, research on the quality of health care
has not been a national priority, a situation that has been
consistent for decades. In fact, over the last 30 years, the ratio
of American dollars spent on basic biomedical research
(through the NIH) to those spent on HSR (through the
agencies designated for this purpose, currently the Agency
for Healthcare Research and Quality) has typically been
around 100:1 (Gray et al., 2003). Why should this be? Basic
research has several important ‘‘marketing’’ advantages. For
example, it often focuses on the pathogenesis of serious
diseases, which are universally understood as threatening to
Congress and voters. The big-ticket items for HSR, on the other
hand, are often highly prevalent chronic conditions that may
not be widely regarded as serious. Moreover, basic research
itself is economically advantageous both to academic medical
centers and for-profit companies that produce drugs and other
patient-care devices. The findings of HSR, on the other hand,
may conflict with vested interests if, for example, a newer
technology was found to be less cost-effective than a cheaper,
older alternative. In addition, there may be few or weak
incentives to implement the results of comparative effective-
ness research in a complex, often profit-driven market such as
that in the United States. The effects of changing American
politics on HSR funding have been reviewed, including the
history of powerful lobbies confronting Congress when they
objected to the findings of HSR studies (Gray et al., 2003).
The US funding for effectiveness research—a type of
HSR—received a boost when President Obama funded the
American Recovery and Reinvestment Act in 2009, which
committed $1.1 billion to fund Comparative Effectiveness
Research. The impetus for this funding was not only to infuse
funds into the ailing economy but also to begin to address the
monumental American increase in health-care spending. In
announcing the funding, the President coincidentally asked a
fundamental and complex HSR question, ‘‘If there0s a blue pill
and a red pill, and the blue pill is half the price of the red pill
and works just as well, why not pay half price for the thing
that0s going to make you well?’’ (CBSNews, 2009). Studies to
compare effectiveness and to understand barriers to adoption
of cost-effective therapies are a cornerstone of HSR. (After the
announcement, the Institute of Medicine sought broad input
about which conditions should receive the most funding,
and 2,606 nominations were received from 1,758 persons; of
100 initial priority topics, four were related to Dermatology:
psoriasis, acne vulgaris, leg ulcers, and psoriatic arthritis.)
Despite the infusion of these funds, however, funding for
HSR in the US remains significantly lower than funding
for biomedical research through the NIH (the President’s
requested FY 2012 budget for the NIH was $32 billion).
EXAMPLES OF HEALTH SERVICES RESEARCH
IN DERMATOLOGY
Basic HSR: development of research measures
Diagnostic and outcomes measures. Fundamental to study-
ing health care is the ability to measure disease and its effects
accurately, which is relatively straightforward if the effect is
straightforward to define and assess (mortality or abnormal
laboratory values, for example). More challenging, however,
is the typical situation in Dermatology in which the clinical
course of disease is a changing rash, patients live with their
conditions rather than die from them, and laboratory
values—if they are altered at all—do not capture the severity
of disease and effects of care on patients’ lives.
Much basic HSR in Dermatology has focused on the
development and testing of accurate tools to measure
complex health states or outcomes such as the diagnosis of
disease (Dominguez et al., 2009) or skin-related quality of life
(Finlay and Khan, 1994; Chren et al., 1997). The example of
clinical severity measures for atopic dermatitis (AD) illustrates
the necessary focused and incremental approach. Dermato-
logic health services researchers studied available measure-
ment tools and concluded that of the 20 published outcomes
measures for AD, only four had adequate measurement
properties such as reliability and validity (Schmitt et al.,
2007). The same investigators developed an international
standardization for core outcome measures for AD and
identified the key domains that should be included in any
outcome tool (Schmitt and Williams, 2010; Schmitt et al.,
2011). This background work is essential to the development
of an accurate measure of clinical severity in AD.
Risk adjustment methods. A notable example of risk
adjustment methods applied to a skin condition is the staging
system for melanoma, recently updated in 2009 (Balch et al.,
2009). The system was developed with an evidence-based
approach, using a large international database that contained
information from nearly 40,000 patients. The current version
also illustrates the continuous improvement in risk-adjust-
ment strategies that are possible as more data are accumu-
lated and analyzed, and as variables not previously in the
staging system are identified and included.
Prediction tools. Quantitative models that predict clinical
outcomes can also identify variables to include in clinical
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Figure 1. Continuum of clinical research. Basic biomedical research at the
bench develops therapies, which are tested in patients for efficacy and in
populations for effectiveness. Health services research examines whether
health-care interventions improve health overall.
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prediction models to be used both by researchers and by
clinicians or patients to understand individual prognoses and
improve outcomes. For example, the staging system for
melanoma cited above has been used as a basis for a web-
based tool that will predict an individual patient’s survival
prognosis (Gershenwald et al., 2010). A predictive tool for
healing of leg ulcers has been developed and tested (Kurd
et al., 2009), and another instrument estimated the risk of
developing melanoma, to assist in the identification of high
risk groups for screening (Fears et al., 2006).
Applied HSR
Outcomes research. A premier example of the systematic
examination of the effects of health care on patients and
society is the 25-year-old Psoralen plus ultraviolet A follow-
up study. This multicenter cohort study carefully followed up
over 1,300 patients with psoriasis who were treated with
Psoralen plus ultraviolet A, and documented many outcomes
of the treatment, including clinical course (Nijsten et al.,
2007), quality of life (McKenna and Stern, 1997), adverse
events (Stern et al., 1980), cost (Stern et al., 1981), and risks
of cancer (Stern, 1990; Stern and Vakeva, 1997; Stern et al.,
1997), cardiovascular disease, and death (Stern and Hui-
bregtse, 2011). Outcomes studies that enroll patients on the
basis of diagnosis rather than treatment type permit compara-
tive effectiveness research among different treatments. For
instance, the Nonmelanoma Skin Cancer Cohort Study
enrolled more than 1,500 patients with the Nonmelanoma
Skin Cancer at the time of diagnosis; both patient-reported
and long-term clinical outcomes after treatment have been
examined (Chren et al., 2007, 2011; Asgari et al., 2009).
Behavioral research. Broadly, behavioral research is the
collection of systematic information about human behavior
and, in the case of HSR, how it affects health. Patients’
health-related behaviors are important to their risks of
developing some skin diseases, and their responses to
treatments. Dermatologic health services investigators have
studied important aspects of skin health behavior, including
the use of sun safety and risk behaviors (Hillhouse et al.,
2010), and patient self-care (Robinson et al., 2008). In
addition, interesting studies on adherence have informed
strategies to increase the likelihood that prescribed treatments
will be adopted by patients (Chisolm et al., 2010).
Implementation research. Some health interventions, such as
an occupational sun safety program (Mayer et al., 2009), are
implemented into the community with variable success.
However, many effective interventions have yet to be
implemented into health care more broadly. The reasons
for this ‘‘roadblock’’ are complex, and are the focus of many
types of HSR, including behavioral research, cost-effective-
ness research, and studies of health disparities and access.
In many cases, fundamental knowledge must be directly
acquired in the field about the reasons underlying the failure
of effective strategies to be implemented (Hajjaj et al., 2010).
For example, barriers to the adoption of sun protection
policies in schools have been identified (Geller et al., 2008).
Needs assessment. Too often, health-care interventions are
introduced and broadly used in the community before
adequate evaluations of need (Hay and Fuller, 2011), efficacy,
effectiveness, and ability to improve health care and health
have been performed. National dermatologic health-care
needs are typically not rigorously determined, but a premier
example is ‘‘Skin conditions in the UK: a Health Care Needs
Assessment,’’ which was updated in 2009 (Schofield and
Williams, 2009); this research on needs and effectiveness can
be directly used to inform health-care planning.
Technology assessment. The use of teledermatology is
increasing rapidly, but this technology is also being assessed
in rigorous ways by dermatologic health services researchers
who have not only examined its diagnostic accuracy but have
also synthesized what is known about its usefulness and cost
(Warshaw et al., 2011).
Research on access to care. The reasons for health inequities
are complex (Sauaia and Dellavalle, 2009), and may be related
to lack of access to health care. In the US, access to dermatologic
care is likely uneven, although the effects on dermatologic health
have not been well studied. Patient socioeconomic barriers or
limited health literacy may lead to poor access (Wich et al.,
2011; Hernandez et al., 2011); obstacles related to health-care
reimbursement may also be important (Resneck et al., 2006).
Research on work force. Because of the importance of
adequate access to care and the expense of training
physicians, determining the optimal number of dermatologists
has significant implications for achieving the best health care.
Studies of this issue have highlighted persistent unmet demand
over time (Kimball and Resneck, 2008) and substantial skin
care provided by non-dermatologists (Armstrong et al., 2009).
Cost and cost-effectiveness analyses. The application of
health economic methodologies to the analysis of dermato-
logic health care had expanded greatly in the past two
decades. We now have estimates of the overall cost of care
for many common skin conditions such as AD (Ellis et al.,
2002) and melanoma (Seidler et al., 2010). Cost-effectiveness
studies require not only accurate determination of monetary
expenditures but also a measurement of treatment effective-
ness. For example, cost-effectiveness analyses of common
therapies for warts (Thomas et al., 2006) and nonmelanoma
skin cancer (Essers et al., 2006) have been conducted.
Effectiveness of therapy can be based on highly specific
outcomes, or more general effects of the therapy and treated
condition on patients’ survival and quality of life, using a
standard metric called utilities. A catalog of dermatologic
utilities has been developed (Chen et al., 2004), which can be
used both for future cost-effectiveness analyses and for further
refinements of the methodology itself.
CHALLENGES TO HEALTH SERVICES RESEARCH IN
DERMATOLOGY
To understand how best to translate scientific discovery into
improved dermatologic health, our specialty shares many of
www.jidonline.org 1005
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the challenges faced by health services researchers overall
(Vargas et al., 2004). First, there are too few qualified
dermatologic health services investigators. As is the case for
the vast majority of medical research, the necessary research
skills in the multidisciplinary methodologies of HSR most
often require focused and intensive post-doctoral research
training, which may be a disincentive to potential research-
ers. Most HSR is conducted in academic medical centers, and
requires a specialized environment with easy access to
expertise in the social sciences and biostatistics, as well as to
computers, specialized software, and the research infrastruc-
ture needed to store, manage, and analyze data directly
collected from patients, or from databases. However, tools
alone are not enough; the research setting must also provide
a supportive and collaborative environment that encour-
ages collaboration across the research spectrum (Figure 1),
and that values patient-based research equally with bench
research. Collaboration with the generalist specialties such
as general internal medicine and geriatrics, which have
long track records in HSR, can enhance and enrich the
environment for dermatologist investigators. Mentoring in
HSR is as important for career development as it is in basic
biomedical research; a useful model is that of a ‘‘mentoring
team’’ in which a few senior experts highly committed to
a mentee’s advancement each provide different aspects
necessary for mentoring, such as scientific mentoring and
academic /career mentoring. A supportive and committed
department Chair is the centerpiece of making the environ-
ment ‘‘work’’ for a health services researcher. Finally, of
course, in the US, substantial increases in research funding
through the NIH and Agency for Healthcare Research and
Quality will be necessary before we can study dermatologic
health care adequately.
CONCLUSION
Health services research in dermatology is growing markedly.
Twenty years ago, the Society for Investigative Dermatology
received very few research abstracts in patient-based research,
and even fewer that studied the care of skin diseases.
Now the Society for Investigative Dermatology receives
many abstracts in HSR, enough to support a robust concurrent
session at the annual meeting. Similarly, over most of the
past 75 years, the Journal only uncommonly published
studies about health care. Now it more regularly features
cutting-edge papers that report results of many types of
HSR studies in dermatology. We need HSR to answer
pressing questions about our health and our investment in
health care, and as a specialty we are beginning to participate
in the response.
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